ST. LOUIS, Mo., Jan. 6 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) has expanded its proteomics offerings with the acquisition of Seppro(R) affinity depletion technology and a library of 700 avian-derived antibodies from GenWay Biotech, Inc. Seppro depletion products enable scientists to measure more precisely the expression of protein biomarkers from a range of mammalian and plant biological samples. This acquisition covers current inventory, production technology and all future rights to produce and distribute the product lines.
The Seppro IgY depletion platform is an antibody-based technology for processing plasma, serum and plant samples. It enables researchers to detect and analyze commonly obscured biomarkers in samples by removing highly abundant proteins. Seppro depletion products are built using chicken-derived IgY antibodies, providing higher selectivity and lower cross-reactivity than other comparable products. The Seppro platform, incorporating SuperMix technology, represents the most complete human depletion system available, removing 14 of the most abundant proteins from human serum or plasma, as well as other high and medium abundant proteins. Additional products are available for the depletion of mouse and rat samples, as well as the industry's only depletion system for the removal of Rubisco.
The library of 700 polyclonal IgY antibodies acquired from GenWay
represents Sigma-Aldrich's first IgY antibody offering. The new antibodies
are derived from chicken embryos and prepared using recombinant antigens.
Chicken antibodies display less cross-reactivity with mammalian proteins,
producing fewer false positive reactions in certain immunochemical assays.
Chicken IgY is also typically more stable than IgG derived from mammalian
species. With the acquisition of the chicken-derived Ig
Copyright©2009 PR Newswire.
All rights reserved